eXoZymes (EXOZ) Q4 2024 earnings summary

Executive summary

• Introduced a novel cell-free, AI-driven enzyme technology for sustainable chemical production, aiming to disrupt traditional petrochemical and cell-based synthetic biology methods.

• Achieved Nasdaq listing on November 13, 2024, despite challenging fundraising conditions for biotech and high-tech sectors.

• Focused initial commercialization on nutraceuticals with pharmaceutical potential, leveraging high-value, low-volume markets for faster go-to-market.

• Continued development of proprietary AI-driven enzyme technology to accelerate biomanufacturing innovation.

• Strengthened leadership with the appointment of a new Chief Commercial Officer experienced in commercializing biotechnologies.

Financial highlights

• Ended 2024 with $9.72 million in cash and cash equivalents, providing liquidity into 2026.

• Total operating expenses for 2024 were $5.9 million, up $4.1 million year-over-year, mainly due to increased R&D and personnel.

• Reported a net loss of $5.9 million for 2024 as a pre-revenue company.

Outlook and guidance

• Plans to launch the first spin-out in Q2 2025, with a dedicated investor call to detail the business case.

• Aims to launch a joint venture later in 2025, with further details pending the first business launch.

• Expects to expand from spin-outs and joint ventures to licensing deals as the business matures.

• Emphasizing commercial applications and partnerships to enter multiple markets rapidly.

• Will consider additional capital raises after the first spin-out, with strong investor interest already present.